MUCOGEL SUSP 125ML

Indications

Approved Uses

Symptomatic relief of heartburn, acid indigestion, gastroesophageal reflux, peptic ulcer pain, gastritis, esophagitis

Dosage & Administration

Children's Dosage

Not recommended for children under 12 years without medical supervision

Dose Adjustment Notes

Renal impairment: avoid or use the lowest effective dose for the shortest duration; increased risk of aluminum accumulation and hypermagnesemia-seek medical advice, especially in moderate-severe CKD. Avoid prolonged continuous use without clinician review (e.g., >14 days).

How to Take

Shake well before use; measure doses with a calibrated spoon/cup. Take 10-15 minutes before meals and at bedtime (or as directed). May be taken undiluted; a small amount of water after the dose is acceptable. Separate from other oral medicines by at least 2 hours (4 hours for tetracyclines/fluoroquinolones/levothyroxine/bisphosphonates when possible).

How to Prepare

Shake well before use. Measure the dose using a suitable measuring device. Do not dilute unless advised by a healthcare professional.

Side Effects

Common Side Effects

Constipation (aluminum hydroxide), diarrhea (magnesium hydroxide), nausea, chalky taste, belching

Side Effect Frequency

Common: constipation (aluminum salts) and diarrhea (magnesium salts), nausea/chalky taste; Uncommon/Rare: hypophosphatemia with prolonged/high-dose aluminum-containing antacid use, hypermagnesemia in renal impairment or prolonged use, and aluminum accumulation/toxicity with long-term use (especially in renal impairment).

Safety & Warnings

Contraindications

Hypersensitivity to any component; severe renal impairment/renal failure; hypophosphatemia (or risk of phosphate depletion) as a precaution/avoid prolonged use; avoid use in undiagnosed acute abdominal pain/possible surgical abdomen

Warnings & Precautions

Avoid prolonged use without medical advice (commonly >14 days); use caution/avoid in renal impairment; separate from other oral medicines by at least 2 hours; risk of hypophosphatemia with prolonged/high-dose use; do not use for undiagnosed abdominal pain or alarm symptoms (GI bleeding, weight loss, dysphagia, persistent vomiting)

Age Restriction

Not recommended under 12 years.

Driving Warning

May Cause Drowsiness

Drug Interactions

Drug Interactions

Decreases absorption of many oral drugs (notably tetracyclines, fluoroquinolones, iron, bisphosphonates, levothyroxine, azole antifungals, and some antivirals); separate by at least 2 hours (up to 4 hours for quinolones/bisphosphonates/levothyroxine when feasible). May increase salicylate excretion (reduced salicylate effect).

Interaction Severity

Clinically significant (often managed as moderate): reduced absorption via chelation/adsorption with tetracyclines, fluoroquinolones, iron, bisphosphonates, levothyroxine, azole antifungals (ketoconazole/itraconazole), and others-separate dosing (prefer 2-4 hours; longer for high-risk pairs).

Special Populations

Pregnancy

Caution

Children

Not recommended for children under 12 years without medical supervision

Kidney Impairment

Severe renal impairment (e.g., CrCl <30 mL/min or dialysis): avoid/contraindicated; mild-moderate impairment: use with caution, lowest effective dose, short duration, monitor for toxicity

Storage & Patient Advice

Storage Conditions

Store below 30°C. Keep bottle tightly closed. Do not freeze. This is a ready-to-use suspension; no reconstitution required.

Preparation Instructions

Shake well before use. Measure the dose using a suitable measuring device. Do not dilute unless advised by a healthcare professional.

Stopping the Medicine

Safe to stop anytime; no tapering required

Patient Counseling

Shake well; measure doses accurately. Take 5-10 mL 10-15 minutes before meals and at bedtime as directed. Separate from other oral medicines by at least 2 hours (prefer 4 hours for tetracyclines/fluoroquinolones/levothyroxine/bisphosphonates). Do not use continuously >14 days without medical advice; seek care for alarm symptoms (GI bleeding, weight loss, persistent vomiting, severe pain). Use caution/seek advice in kidney disease. Possible constipation (aluminum) or diarrhea (magnesium).

Monitoring Requirements

No routine monitoring for short-term OTC use. If prolonged/high-dose use or renal impairment: monitor renal function and electrolytes (especially magnesium and phosphate) and watch for signs of aluminum toxicity/hypermagnesemia.

Pharmacology

Mechanism of Action

Aluminum hydroxide and magnesium hydroxide neutralize gastric acid and increase intragastric pH; oxethazaine is a topical local anesthetic that blocks voltage-gated sodium channels in mucosal nerves, reducing pain/burning from acid irritation.

Onset of Action

Within minutes (typically ~5-15 minutes) for symptom relief.

Half-Life

Not clinically applicable/meaningful for routine use because the primary effect is local in the GI tract with minimal systemic absorption; no standard half-life is used for dosing.

Bioavailability

Minimal systemic absorption for aluminum and magnesium hydroxide. Less than 1/3 of the administered dose of oxethazaine is absorbed.

Metabolism

Aluminum hydroxide and magnesium hydroxide are not metabolized and act locally in the GI lumen; oxethazaine is minimally systemically absorbed and any absorbed fraction is hepatically metabolized.

Excretion

Aluminum hydroxide: largely unabsorbed, excreted in feces as insoluble salts; small absorbed fraction eliminated renally. Magnesium hydroxide: mostly fecal; absorbed magnesium is renally excreted. Oxethazaine: minimal systemic absorption; elimination primarily via feces/biliary with very small urinary recovery.

Protein Binding

Unknown / not clinically relevant due to minimal systemic absorption (especially for the antacid components).

Product Information

Available Dosage Forms

Oral suspension

OTC Alternatives

Other OTC antacids: aluminum hydroxide/magnesium hydroxide suspensions (e.g., Maalox-type), alginate-based antacids (e.g., sodium alginate combinations), calcium carbonate products; H2 blockers (e.g., famotidine) where available OTC.

Gi Condition

Acid Reflux/GERD

Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.